Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Cancer Discovery
|
January 13, 2021
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia
Stefan Bjelosevic, Emily Gruber, Andrea Newbold, et al.
British Journal of Haematology
|
March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study
Kate Manos, Leonid Churilov, Andrew Grigg, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 29, 2023
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma
Danielle H Oh, Xiao Ma, Simon J Hogg, et al.
Targeted Oncology
|
October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
Eliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Blood Advances
|
December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Gareth P Gregory, Shaji Kumar, Ding Wang, et al.
Internal Medicine Journal
|
March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Leukemia
|
December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
Darren C Phillips, Sha Jin, Gareth P Gregory, et al.
Blood Advances
|
April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Leukemia
|
April 23, 2022
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
Jonathan Wong, Emily Gruber, Belinda Maher, et al.
Ejhaem
|
August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Cancer Discovery
|
January 13, 2021
Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia
Stefan Bjelosevic, Emily Gruber, Andrea Newbold, et al.
British Journal of Haematology
|
March 14, 2024
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study
Kate Manos, Leonid Churilov, Andrew Grigg, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 29, 2023
Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma
Danielle H Oh, Xiao Ma, Simon J Hogg, et al.
Targeted Oncology
|
October 23, 2021
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
Eliza A Hawkes, Tycel Phillips, Lihua Elizabeth Budde, et al.
Blood Advances
|
December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Gareth P Gregory, Shaji Kumar, Ding Wang, et al.
Internal Medicine Journal
|
March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Leukemia
|
December 13, 2019
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
Darren C Phillips, Sha Jin, Gareth P Gregory, et al.
Blood Advances
|
April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Leukemia
|
April 23, 2022
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
Jonathan Wong, Emily Gruber, Belinda Maher, et al.
Ejhaem
|
August 19, 2024
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, et al.
Page
of 4